Key result
Lower extremity DVT in hospitalized COVID-19 patients is linked to ~3-fold higher mortality.
Why the study?
The prevalence, risk factors, prognosis, and potential thromboprophylaxis strategies for deep vein thrombosis in hospitalized patients with COVID-19 required evaluation.
What are the prevalence, risk factors, prognosis, and effect of venous thromboembolism prophylaxis on deep vein thrombosis in hospitalized patients with COVID-19?
Cohort (n=143)
No
What are the prevalence, risk factors, prognosis, and effect of venous thromboembolism prophylaxis on deep vein thrombosis in hospitalized patients with COVID-19?
Hospitalized patients with COVID-19 have a high prevalence of lower extremity DVT (46.1%), which is independently associated with elevated CURB-65 score, Padua score, and D-dimer levels, and strongly linked to increased mortality.
Answers are grounded in this paper and cite their sources.
DVT links to higher mortality in hospitalized COVID-19; hypothesis-generating and should not yet change practice.
Background: To investigate deep vein thrombosis (DVT) in hospitalized patients with coronavirus disease 2019 (COVID-19), we performed a single institutional study to evaluate its prevalence, risk factors, prognosis, and potential thromboprophylaxis strategies in a large referral and treatment center. Methods: We studied a total of 143 patients with COVID-19 from January 29, 2020 to February 29, 2020. Demographic and clinical data, laboratory data, including ultrasound scans of the lower extremities, and outcome variables were obtained, and comparisons were made between groups with and without DVT. Results: Of the 143 patients hospitalized with COVID-19 (age 63±14 years, 74 [51.7%] men), 66 patients developed lower extremity DVT (46.1%: 23 [34.8%] with proximal DVT and 43 [65.2%] with distal DVT). Compared with patients who did not have DVT, patients with DVT were older and had a lower oxygenation index, a higher rate of cardiac injury, and worse prognosis, including an increased proportion of deaths (23 [34.8%] versus 9 [11.7%]; P =0.001) and a decreased proportion of patients discharged (32 [48.5%] versus 60 [77.9%]; P <0.001). Multivariant analysis showed an association only between CURB-65 (confusion status, urea, respiratory rate, and blood pressure) score 3 to 5 (odds ratio, 6.122; P =0.031), Padua prediction score ≥4 (odds ratio, 4.016; P =0.04), D-dimer >1.0 μg/mL (odds ratio, 5.818; P <0.014), and DVT in this cohort, respectively. The combination of a CURB-65 score 3 to 5, a Padua prediction score ≥4, and D-dimer >1.0 μg/mL has a sensitivity of 88.52% and a specificity of 61.43% for screening for DVT. In the subgroup of patients with a Padua prediction score ≥4 and whose ultrasound scans were performed >72 hours after admission, DVT was present in 18 (34.0%) patients in the subgroup receiving venous thromboembolism prophylaxis versus 35 (66.0%) patients in the nonprophylaxis group ( P =0.010). Conclusions: The prevalence of DVT is high and is associated with adverse outcomes in hospitalized patients with COVID-19. Prophylaxis for venous thromboembolism may be protective in patients with a Padua protection score ≥4 after admission. Our data seem to suggest that COVID-19 is probably an additional risk factor for DVT in hospitalized patients.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2020) conducted a cohort in Hospitalized COVID-19 investigating deep vein thrombosis (DVT) (n=143). Lower extremity deep vein thrombosis (DVT) vs. No lower extremity DVT was evaluated on Mortality (proportion of deaths) (p=0.001). Lower extremity DVT occurred in 46.1% of hospitalized COVID-19 patients and was associated with higher mortality compared with no DVT.
Synapse has enriched 10 related papers. Consider them for comparative context: